日本感染症学雑誌第81巻第5号
|
|
|
- ゆりな たけくま
- 7 years ago
- Views:
Transcription
1
2 Fig.1 Testprincipleof DUOI µ
3 Table1 HIV antigenantibodydetectionassay Assaykit DUO GenscreenPlus HIV AgAb Enzygnost HIV Integral Method ELFA ELFA ELISA ELISA Solidphase Antibody detection HIV1gp16(protein) HIV1groupO gp41 (synthetic) HIV2gp6(synthetic), biotinylated HIV1gp41, HIV1groupO gp41 HIV2gp6 (syntheticpeptide) HIV1gp16 (recombinant) HIV1groupO gp41 (synthetic) HIV2gp6(synthetic) HIV1gp41(recombinant andsynthetic) HIV1groupO gp41 (recombinant) HIV2gp6(recombinant) Antigen detection Antip24mouse monoclonal Antip24mouse monoclonal Antip24mouse monoclonal Antip24rabbit polyclonal Conjugate Antibody detection HIV1gp16(protein) HIV1groupO gp41 (synthetic) HIV2gp6(synthetic), biotinylated AntihumanIgGmouse monoclonallabeledwith ALP HIV1gp41, HIV1groupO gp41, HIV2gp6(synthetic) labeledwithpod HIV1gp41(recombinant andsynthetic) HIV1groupO gp41 (synthetic) HIV2gp6(synthetic), biotinylated Antigen detection Antip24rabbitpolyclonal (biotinylated) Antip24rabbitpolyclonal (biotinylated) Antip24sheeppolyclonal (biotinylated) Antip24mouse monoclonal(biotinylated) Samplevolume(μL) Time(min) Support VIDASautomated analyzer VIDASautomated analyzer Microplate Microplate µ µ µ
4 Table2 ResultsofHIVpositiveand negative specimensby 11HIVpositive plasmaspecimens 1,228HIVnegative plasmaspecimens Sensitivity 1% (11/11) Specificity 99.8% (1,225/1,228) Resultsof Positive 11 Negative 1,225 Table Resultsof falsepositivespecimensbyotherassays Antigenantibodydetectionassay Antibodyassay NAT sampleno. DUO Genscreen PlusHIV AgAb EnzygnostHIV Integral PA (GENEDIA HIV 1/2Mix) WB (LABBLOT 1,2) AMPLICOR HIV1Monitor Ver.1.5 TV a c copies/ml X <4 X <4 B <4 a TV:testvalue<.25:Negative,.25:Positive b TV:testvalue<.25:Negative,.25 TV<.5:Borderline,.5:Positive c.:cutofindex
5 Table4 Resultsof DUO falsepositivespecimensby NAT (AMPLICOR HIV1Monitor Ver.1.5) WB (LABBLOT 1,2) PA (GENEDIA HIV 1/2Mix) DUO Sample No. TV a.6 GM66 HIV1p GM6 6.1 GM GM1.45 GM15..4 GM69. GM GM82..9 GM GM GM15.2 GM11.6 GM1 a TV:testvalue<.25:Negative,.25 TV<.5:Borderline,.5:Positive b TV:testvalue<.25:Negative,.25:Positive Table5 ResultsofHIV antigenantibodydetectionassay,antibodyassay,antigenassay,andnucleic acidtest(nat)onworldwidehiv PerformancePanel(WWRB2) NAT Antibodyassay Antigenantibodydetectionassay WWRB2 RocheRNA RTPCR a EIA (AbbotHIV 1/2) a Enzygnost HIV Integral GenscreenPlus HIV AgAb c Genotype No. 1.2 O A 2.1 G G 4.9 A G HIV G 8.11 A 9. negative HIV C 12. A D 1.9 D D D C C C B 2.5 E E E HIV2 25. B B/D 2.22 F B 29.1 negative a Datafrom paneldatasheet b TV:testvalue<.25:Negative,.25:Positive c.:cutofindex
6 Table6 Comparison ofdetection limitsby antigenantibody detection assaysusing WorldwideHIV PerformancePanel (WWRB2) Genotype PanelNo. Antigenantibody detectionassay 1:1 1:1 2 1:1 1:1 4 1:1 5 1:1 6 A WWRB22 (TV a ) VIDUSHIV DUO ( ) Genscreen( c ) Enzygnost() (19.46) d (>1.86) (16.6) (1.51) (>1.86) (> 6.1) (1.41) (1.9) (>1.86) (> 6.1) (2.42) (.) (5.1) (.6) (.2) (.) (.) (.4) (.) B WWRB226 (TV) Genscreen() Enzygnost() (22.5) (>1.86) (2.8) (11.) (>1.86) (> 6.1) (15.1) (.12) (>1.86) (> 6.1) (.5) (.16) (>16.99) (.5) (.4) (.) (.16) () (.) (.61) C WWRB2 (TV) Genscreen() Enzygnost() (2.46) (>1.86) (.19) (1.91) (>1.86) (> 6.1) (16.8) (2.59) (>1.86) (> 6.1) (4.19) () (>16.56) (.15) (.55) (2.44) (.4) (.15) (.54) D WWRB2 (TV) Genscreen() Enzygnost() (12.4) (>1.86) (.64) (2.82) (>1.86) () (1.42) (.19) (2.) (1.5) (.2) () (.54) (.4) () (.2) (.) () E WWRB22 (TV) Genscreen() Enzygnost() (1.58) (>1.86) (11.4) (9.9) (>1.86) () (.4) (1.2) (>1.86) () (.9) () (6.) (.) (.1) (.81) (.4) () F WWRB228 (TV) Genscreen() Enzygnost() (22.8) (>1.86) (.2) (1.4) (>1.86) () (.) (2.1) (>1.86) () (2.6) (.) (1.) (.24) (.6) (1.4) () (.1) (.42) G WWRB24 (TV) Genscreen() Enzygnost() (2.44) (>1.86) (2.54) (1.98) (>1.86) (> 6.1) (18.85) (4.94) (>1.86) (> 6.1) (9.2) (.5) (>15.2) (1.2) (1.4) () (2.) (.) (.2) (.48) O WWRB (TV) Genscreen() Enzygnost() (2.1) (2.48) (>1.86) (> 6.1) (.8) (.2) (>1.86) (> 6.1) (.1) (1.4) (1.2) () (.4) (.) () (.2) (.4) () HIV2 WWRB1 (TV) Genscreen() Enzygnost() (24.92) (>1.86) (2.88) (9.49) (>1.86) (> 6.1) (1.4) (1.84) (11.9) () (.65) () (.45) (2.9) (.16) (.6) (.2) () a TV:testvalue<.25:Negative,.25:Positive b TV:testvalue<.25:Negative,.25 TV<.5:Borderline,.5:Positive c.:cutofindex d :nottested
7 Table ResultsofantigenantibodydetectionassaysandantibodyassayonHIV p24antigenmixedtiterperformancepanel(pra) PRA Antigenantibodydetectionassay Antigenassay Antibodyassay No. group VIDAS HIV DUO Genscreen PlusHIV AgAb Enzygnost HIV Integral EIA (AbbotHIV p24antigen) d PA (GENEDIA HIV 1/2Mix) a b negative c negative a Earlyseroconversionsample b Hightiterantibodysample c Negativecontrolsample d Datafrom paneldatasheet Table8 ComparisonofHIV p24antigendetectionlimitusingtwofolddilutedspecimensofculturedisolatehiv1ib Assay Twofolddilutedspecimen Antigen assay P24I p24ag pg/ml a Antigenantibody detection assay DUO GenscreenPlusHIV AgAb EnzygnostHIV Integral TV c d a p24agpg/ml:<.:negative,.and<5.:equivocal, 5.:Positive b TV:testvalue<.25:Negative,.25:Positive c TV:testvalue<.25:Negative,.25 TV<.5:Borderline,.5:Positive d.:cutofindex
8 Table9 Comparisonofantigendetectionlimitsbyantigenantibodydetectionassaysusingantigenpositivespecimensin thepanel PanelNo. Agvolume Antigenantibody detectionassay 1:1 1:2 1:4 1:8 1:16 1:2 1:64 1:128 p24antigen detectionlimits PRB964 (AK) 256.2pg/mL DUO TV a GenscreenPlus c HIV AgAb EnzygnostHIV Integral d. 4.pg/mL 2.pg/mL 2.pg/mL 128.1pg/mL PRA5 11.pg/mL DUO GenscreenHIV AgAb EnzygnostHIV Integral TV TV pg/mL 56.5pg/mL 56.5pg/mL 11.pg/mL PRA1 9.pg/mL DUO GenscreenHIV AgAb EnzygnostHIV Integral TV TV pg/mL 9.pg/mL 9.pg/mL 9.pg/mL a TV:testvalue<.25:Negative,.25:Positive b TV:testvalue<.25:Negative,.25 TV<.5:Borderline,.5:Positive c.:cutofindex d :nottested
9 Table1 ComparisonoftheperformanceofHIV antigenantibodydetectionassay,antigenassay,nucleicacidtest(nat)andantibodyassayon1hiv1seroconversionpanels Antibodyassay NAT Antigenassay Antigenantibodydetectionassay Days since 1st bleed PanelNo. EIA (Abbot HIV 1/2) a PA (GENEDIA HIV 1/2Mix) RocheRNA RTPCR a Abbot HIVAg a P24I Enzygnost HIV Integral Genscreen PlusHIVAgAb VIDAS HIV DUO VIDAS HIV pg/ml e d TV c.52 f PRB (AK) > >4 > >4 > PRB91.4 (AL) PRB (AM)2 >4. >6.5 > PRB99(E)4.6.1 (AN) >4. > >4. > >6.5 > PRB (AU) > > PRB (BA) >4. > >4. > PRB (BB) > > PRB (BC) > PRB (BD) >4..45 > PRB (BE) > adatafrom paneldatasheet btv:testvalue<.25:negative,.25:positive ctv:testvalue<.25:negative,.25 TV<.5:Borderline,.5:Positive d.:cutofindex ep24agpg/ml:<.:negative,.and<5.:equivocal, 5.:Positive f:nottested
10 et al. et al.
11 et al.
Key words: HIV screening kit, window period, p24antigen, enzyme-linked fluorescent assay
Key words: HIV screening kit, window period, p24antigen, enzyme-linked fluorescent assay Fig.1 @ A principle of assay The assay comprises of two reactions. The first reaction, for the detection of anti-hiv-
橡stat3.PDF
1 2 3 4 5 T + D T nod T + nod D T D T + nod T + D D + nod T + T + + T a a + c d b + d b b + d = 1 specificity c a + c = 1 sensitivity a a + b d c + d a + c a + b + c + d a + b a + b + c + d a + d a + b
234 50cm
234 50cm () 1 10 2 3 4 1 5 6 2 2 1 7 ( ー ) っ ー っ 8 1 2 10 10 2m 4m 6m 15m 457-2472 585-1154 9 10 2 60 2 100 RC SRC 30 80 500 1 500 500 ) 10 B b A 2 A B 2m 457-2473 585-1154 11 20m a 2m 3 3 1m 75cm 120cm
48 * *2
374-1- 17 2 1 1 B A C A C 48 *2 49-2- 2 176 176 *2 -3- B A A B B C A B A C 1 B C B C 2 B C 94 2 B C 3 1 6 2 8 1 177 C B C C C A D A A B A 7 B C C A 3 C A 187 187 C B 10 AC 187-4- 10 C C B B B B A B 2 BC
PowerPoint プレゼンテーション
0 1 2 3 4 5 6 1964 1978 7 0.0015+0.013 8 1 π 2 2 2 1 2 2 ( r 1 + r3 ) + π ( r2 + r3 ) 2 = +1,2100 9 10 11 1.9m 3 0.64m 3 12 13 14 15 16 17 () 0.095% 0.019% 1.29% (0.348%) 0.024% 0.0048% 0.32% (0.0864%)
2 3
Sample 2 3 4 5 6 7 8 9 3 18 24 32 34 40 45 55 63 70 77 82 96 118 121 123 131 143 149 158 167 173 187 192 204 217 224 231 17 285 290 292 1 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38
( ) ver.2015_01 2
1 1.1 1.2 1.3 2 ( ) 2.1 2.2 2.3 2.4 3 4 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 4.9 5 5.1 5.2 5.3 5.4 6 6.1 6.2 6.3 7 7.1 7.2 7.3 8 ver.2015_01 2 1 1.1 1.2 1.3 ver.2015_01 3 2 2.1 2.2 2.3 ver.2015_01 4 2.4 ver.2015_01
広報さっぽろ 2016年8月号 厚別区
8/119/10 P 2016 8 11 12 P4 P6 P6 P7 13 P4 14 15 P8 16 P6 17 18 19 20 P4 21 P4 22 P7 23 P6 P7 24 25 26 P4 P4 P6 27 P4 P7 28 P6 29 30 P4 P5 31 P5 P6 2016 9 1 2 3 P4 4 P4 5 P5 6 7 8 P4 9 10 P4 1 b 2 b 3 b
untitled
351 351 351 351 13.0 0.0 25.8 1.0 0.0 6.3 92.9 0.0 80.5 0.0 1.5 15.9 0.0 3.5 13.1 0.0 30.0 54.8 18.0 0.0 27.5 1.0 0.0 2.5 94.7 0.0 91.7 0.0 1.3 14.7 0.0 3.8 14.4 0.0 25.0 50.5 16.0 0.0 27.5 2.0 0.0 2.5
H27 28 4 1 11,353 45 14 10 120 27 90 26 78 323 401 27 11,120 D A BC 11,120 H27 33 H26 38 H27 35 40 126,154 129,125 130,000 150,000 5,961 11,996 6,000 15,000 688,684 708,924 700,000 750,000 1300 H28
北アルプス_燕岳～穂高_－2.doc
1 ( )22 2001 2226 30 1300m 27kg 2 JR 1000 22 10 3 500-400 au 300 N 2763m 4 N N 10 N 500m PM9:00 5 ( 2 ) 7 23 2001 2226 10 N N 40 10 30 6 5m N N N 12 3 49 30 20 2922m 7 K ( ) U S N ( ) 50 15 N 35 (2758m)
2 7 ( ) µ 
190117_Quidel社カタログ改訂【初校】.indd
RESEARCH KITS AND REAGENTS Quidel 1979 1984 MicroVue 2016 3 Immutopics MicroVue 50 ISO 13485:2003 ELISA Quidel Specialty Products is the option for all your research, biosafety and cytotoxicity testing
) 9 81
4 4.0 2000 ) 9 81 10 4.1 natural numbers 1, 2, 3, 4, 4.2, 3, 2, 1, 0, 1, 2, 3, integral numbers integers 1, 2, 3,, 3, 2, 1 1 4.3 4.3.1 ( ) m, n m 0 n m 82 rational numbers m 1 ( ) 3 = 3 1 4.3.2 3 5 = 2
21 1 1 1 2 2 5 7 9 11 13 13 14 18 18 20 28 28 29 31 31 34 35 35 36 37 37 38 39 40 56 66 74 89 99 - ------ ------ -------------- ---------------- 1 10 2-2 8 5 26 ( ) 15 3 4 19 62 2,000 26 26 5 3 30 1 13
CHEMOTHERAPY JUNE 1986
VOL. 34 S-3 CHEMOTHERAPY Fig. 1 Structural formula of L-105 CHEMOTHERAPY JUNE 1986 VOL. 34 S-3 CHEMOTHERAPY Table 1 Antibacterial spectra of L-105 against gram negative anaerobic rods Inoculum 106 cells/ml
, 1. x 2 1 = (x 1)(x + 1) x 3 1 = (x 1)(x 2 + x + 1). a 2 b 2 = (a b)(a + b) a 3 b 3 = (a b)(a 2 + ab + b 2 ) 2 2, 2.. x a b b 2. b {( 2 a } b )2 1 =
x n 1 1.,,.,. 2..... 4 = 2 2 12 = 2 2 3 6 = 2 3 14 = 2 7 8 = 2 2 2 15 = 3 5 9 = 3 3 16 = 2 2 2 2 10 = 2 5 18 = 2 3 3 2, 3, 5, 7, 11, 13, 17, 19.,, 2,.,.,.,?.,,. 1 , 1. x 2 1 = (x 1)(x + 1) x 3 1 = (x 1)(x
Characterization of Anti-HBs Antigen Monoclonal Antibodies and Application to the Subtyping Yoshiya YOSHIDA, Yumiko FURUYA, Masayasu INOUE, Akiyoshi MATSUSHIMA and Kazumasa ODA Kanagawa Prefectural Public
Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood
Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood Fig.1 Distribution of the cases with bacterial meningitis by age and pathogens Chiba
Key words : influenza, nested-pcr, serotype
Key words : influenza, nested-pcr, serotype Table 1 Sequence of PCR primers used to detect HA gene of influenza virus 524 清水 Fig. 1 Detection of PCR product 英明 他 (lstpcr) Table 2 Results method Fig. 2
Table 1 Bacteriae to be tested (1) Gram positive cocci Coagulase positive staphylococcus Coagulase negative staphylococcus Streptococcus pneumoniae Gr
Chlamydia trachomatis Key words: chlamydial antigen, ELISA, bacteria, cross reaction, respiratory infection C. trachomatis Branhamella catarrhalis C. trachomatis C. trachomatis Chlamydia trachomatis (C.
あさひ indd
2006. 0. 2 2006. 0. 4 30 8 70 2 65 65 40 65 62 300 2006. 0. 3 7 702 22 7 62802 7 385 50 7 385 50 8 385 50 0 2 390 526 4 2006. 0. 0 0 0 62 55 57 68 0 80 5000 24600 37200 0 70 267000 500000 600 2 70 70 267000
Japanese Journal of Transfusion Medicine, Vol. 39. No. 4 39(4): 720-725, 1993 COMPARISON OF THE SENSITIVITY OF ABC-MACE, MACE, MAIPA AND FCM FOR THE DETECTION OF ANTI-PLATELET ALLOANTIBODIES Satoru Kosugi,
YK170 17β-Estradiol EIA キット
YK170 17 - Estradiol EIA FOR RESEARCH LABORATORY USE ONLY 418-0011 2480-1 FAX: 0544-22-2770 TEL: 0544-22-2771 Website: www.yanaihara.co.jp E-mail: ask@yanaihara.co.jp . 2. 3. 4. 5 6. 7. 8 10. 11. 11 1
CONTENTS
2015.8 CONTENTS 01 06 24 42 48 58 86 88 104 106 120 126 155 24 30 365 TV MONO-LIFE BALANCE - Vietas - 10 PLAN 01 6 3 Kitchen Bed room Entrance Desk Living room 3 P 06 PLAN 02 PLAN 03 5 4 Entrance Core
Key words: Legionella, urinary antigen, enzymeimmunoassay (EIA), rapid diagnosis
Key words: Legionella, urinary antigen, enzymeimmunoassay (EIA), rapid diagnosis lymerase chain reaction(pcr) EIA kit Table1 @ Reference strains used in this study Table2 @ Comparison between Biotest and
Fig. 1. Structures of NM394, NAD-358 and NAD-245 Fig. 2. Typical HPLC chromatograms of NM394 in human plasma by organic solvent extraction method (a): Blank plasma (b): Plasma spiked with NM394 and internal
空き容量一覧表（154kV以上）
1/3 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量 覧 < 留意事項 > (1) 空容量は 安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 熱容量を考慮した空き容量を記載しております その他の要因 ( や系統安定度など ) で連系制約が発 する場合があります (3) 表 は 既に空容量がないため
2/8 一次二次当該 42 AX 変圧器 なし 43 AY 変圧器 なし 44 BA 変圧器 なし 45 BB 変圧器 なし 46 BC 変圧器 なし
1/8 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量一覧 < 留意事項 > (1) 空容量は目安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 特に記載のない限り 熱容量を考慮した空き容量を記載しております その他の要因 ( や系統安定度など ) で連系制約が発生する場合があります (3)
1
1 1 2 3 4 2 3 4 5 R 6 7 1 2 3 4 1 2 3 4 8 1 1 2 3 4 1 2 3 9 10 R A 85 U 11 8605 66 E 8 8 0 0 6 U W 6 B 38 U W6B28 U 12 W A 65 14 U W A 5B 12 U 6B 65 13 R A 85 F 14 15 16 17 18 19 20 21 22 23 24 25 26 27
０４年度LS民法Ⅰ教材改訂版.PDF
?? A AB A B C AB A B A B A B A A B A 98 A B A B A B A B B A A B AB AB A B A BB A B A B A B A B A B A AB A B B A B AB A A C AB A C A A B A B B A B A B B A B A B B A B A B A B A B A B A B A B
2009 Aida et al. Caries Res 2006;40 2000 100 % 78.7 88.0 96.6 98.8 98.8 98.8 100.0 100.0 100 75 69.4 50 75.3 74.8 73.3 73.1 73.0 72.4 71.8 71.7 51.7 40.2 69.4 68.8 73.6 25 22.3 32.8 21.9 22.9 22.1
Table 1 Comparison with three HIV antigen and antibody screening tests Principle Detection of anti-hiv antibody gp41 HIV-1 Detection of HIV antigen Ti
技術論文 ルミパルス f を用いた 同時検出試薬の 性能評価 石垣 卓也 1) 康 東天 2) 服部佳奈子 1) 山中 基子 1) 堀田多恵子 1) 1) 九州大学病院検査部 812-8582 福岡県福岡市東区馬出 3-1-1 2) 九州大学大学院医学研究院臨床検査医学分野 要 旨 今回 富士レビオ社が開発した第 4 世代検査試薬である ルミパルス 以下 本試薬 の性能評価を行っ た 同時再現性 日差再現性
Section Section Section Table of Contents Section 6 Section 7 Section 8 Section 4 Section 0 Section 5 Section 9 Section Section Section Section 4 Section 5 Section 9 Section 0 Section Section 6 Section
1 P2 P P3P4 P5P8 P9P10 P11 P12
1 P2 P14 2 3 4 5 1 P3P4 P5P8 P9P10 P11 P12 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 & 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 1! 3 2 3! 4 4 3 5 6 I 7 8 P7 P7I P5 9 P5! 10 4!! 11 5 03-5220-8520
WECPNL = LA +10log10 N 27 N = N 2 + 3N3 + 10( N1 + N 4) L A N N N N N 1 2 3 4 Lden Lden Lden Lden LAE L pa pa 2 a /10 LpA = 20 log 10 ( pa = p 10 ) n na p0 p na n an n p0 2 Lp p L p
12 重度訪問介護重度障害者等の場合 ( 重度訪問介護 Ⅰ)
請求サービスコードと決定サービスコードの対応表 網掛けは 平成 30 年 4 月報酬改定等により 追加及び変更になったものサービス種類決定サービスサービス種類サービス内容請求サービスコードコードコード 11 居宅介護居宅における身体介護 111111~111999 111000 112000~112058 112061~112364 11A001~11BW60 通院介助 ( 身体介護を伴う場合 )
取扱説明書 -詳細版- 液晶プロジェクター CP-AW3019WNJ
B A C D E F K I M L J H G N O Q P Y CB/PB CR/PR COMPONENT VIDEO OUT RS-232C LAN RS-232C LAN LAN BE EF 03 06 00 2A D3 01 00 00 60 00 00 BE EF 03 06 00 BA D2 01 00 00 60 01 00 BE EF 03 06 00 19 D3 02 00
特許侵害訴訟における無効の主張を認めた判決─半導体装置事件−
[*1847] 12 4 11 10 364 54 4 1368 1710 68 1032 120 X Y 6.8.31 29 3 875 X Y 9.9.10 29 3 819 Y 320275 391468 46 12 21 35 2 6 3513745 39 1 30 320249 1) 1 39 1 [*1848] 2) 3) Y 10 51 2 4 39 5 39 1 3 139 7 2
表1.eps
Vol.1 C ontents 1 2 cell-free EMBO J Proc. Natl. Acad. Sci. USA NatureEMBO J 3 RNA NatureEMBO J Nature EMBO J 4 5 HCV HCV HCV HCV RNA HCV in situ 6 7 8 Nat Struct Mol Biol J Biol Chem Nat Commun J Virol
VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )
CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative
さくらの個別指導 ( さくら教育研究所 ) 1 φ = φ 1 : φ [ ] a [ ] 1 a : b a b b(a + b) b a 2 a 2 = b(a + b). b 2 ( a b ) 2 = a b a/b X 2 X 1 = 0 a/b > 0 2 a
![さくらの個別指導 ( さくら教育研究所 ) 1 φ = φ 1 : φ [ ] a [ ] 1 a : b a b b(a + b) b a 2 a 2 = b(a + b). b 2 ( a b ) 2 = a b a/b X 2 X 1 = 0 a/b > 0 2 a](/thumbs/97/131721994.jpg "さくらの個別指導 ( さくら教育研究所 ) 1 φ = φ 1 : φ [ ] a [ ] 1 a : b a b b(a + b) b a 2 a 2 = b(a + b). b 2 ( a b ) 2 = a b a/b X 2 X 1 = 0 a/b > 0 2 a")
φ + 5 2 φ : φ [ ] a [ ] a : b a b b(a + b) b a 2 a 2 b(a + b). b 2 ( a b ) 2 a b + a/b X 2 X 0 a/b > 0 2 a b + 5 2 φ φ : 2 5 5 [ ] [ ] x x x : x : x x : x x : x x 2 x 2 x 0 x ± 5 2 x x φ : φ 2 : φ ( )
- 1 -
- 1 - HIV cmc cmc - 2 - cmc() ( ) 5-3 - - 4 - (1) (2) (3) ( ) - 5 - 0537-73-2662 0537-35-2971 0548-63-1251 9 00 16 00-6 - - 7 - 2 3 4 5 6 1,328 1,848 2,368 2,888 3,408-8 - - 9 - - 10 - - 11 - 3-12 - (
x, y x 3 y xy 3 x 2 y + xy 2 x 3 + y 3 = x 3 y xy 3 x 2 y + xy 2 x 3 + y 3 = 15 xy (x y) (x + y) xy (x y) (x y) ( x 2 + xy + y 2) = 15 (x y)
x, y x 3 y xy 3 x 2 y + xy 2 x 3 + y 3 = 15 1 1977 x 3 y xy 3 x 2 y + xy 2 x 3 + y 3 = 15 xy (x y) (x + y) xy (x y) (x y) ( x 2 + xy + y 2) = 15 (x y) ( x 2 y + xy 2 x 2 2xy y 2) = 15 (x y) (x + y) (xy
一般外科手術機器_14_表1
General 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 General Table of Contents Pages 1-6 2 3 4 5 6 Pages 7-16 8 10 No.3 11 No.4 13 14 15 Pages 17-38 18 21 22 25 26 28
高校生の就職への数学II
II O Tped b L A TEX ε . II. 3. 4. 5. http://www.ocn.ne.jp/ oboetene/plan/ 7 9 i .......................................................................................... 3..3...............................
橡６ 中表紙（教育施設）.PDF
10 i ii 14 1 2 52 53 55 56 57 63 2 3 5 6 13 13 14 14 15 1 3 10 3 4 50 11 7 6 1 45,813.68 19,120.95 3 17,979.75 63,793.43 2,501.74 1,458.27 23 4,226.95 76 2,277.28 17 1,264.41 5 1,768.60 26 2,378.96 9 2,126.92
-1 - -2 - -3 - -4 - -5 - -6 - -7 - -8 - -9- 44-10 - -11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - - 26 - - 27 - 372 304-28 - - 29 - - 30 - - 31
LCR e ix LC AM m k x m x x > 0 x < 0 F x > 0 x < 0 F = k x (k > 0) k x = x(t)
338 7 7.3 LCR 2.4.3 e ix LC AM 7.3.1 7.3.1.1 m k x m x x > 0 x < 0 F x > 0 x < 0 F = k x k > 0 k 5.3.1.1 x = xt 7.3 339 m 2 x t 2 = k x 2 x t 2 = ω 2 0 x ω0 = k m ω 0 1.4.4.3 2 +α 14.9.3.1 5.3.2.1 2 x
CBA Kit Manual Human
BD Pharmingen Cytometric Bead Array (CBA) Kit Manual Human Th1/Th2 Cytokine CBA BD Biosciences Section 1 1 Multiplexing BD Cytometric Bead Array CBA Multiplexing BD CBA CBA ELISA ELISA BD Human Th1/Th2
〈企業特集：検査機器・試薬・技術の新たな展開〉新規マイコプラズマ抗原検査キット—プロラスト®Myco
New immunochromatographic assay kit for Mycoplasma pneumoniae infection 'PRORAST Myco' Shohei Ohshima, Yasushi Shimada, Atsuko Minagawa, Kazuyuki Sugiyama and Yumiko Hirayama Mycoplasma pneumoniae infection
Ab-Match Assembly Human PAP1 (REG3a) Kit
CODE No. 323 For Research Use Only, Not for use in diagnostic procedures. Ab-Match Assembly Human PAP1 (REG3α) Kit For technical material or related information, please refer to http://ruo.mbl.co.jp/product/abmatch/abmatch.html.
2015taisetumatome.rtf
B B B( ) B3 - B3 1 3g 1/3 B 1. B1() B1() 2. B2() B2() 3. B5() B5() 4. B6() B6()( ) 5. B12() B12() 6. 1q60 160m 50m 50m 20m 8520 80 10 64 5075 30 80 B B 1 30 BB BC EPA . ?? 6 C E C 1 30 1 0.4mg4
外国語教育センタージャーナル第9号
1. 1 35 45 2. 1 2 2 2013 5 1 31 2 40 3 37 4 40 2 17 2 5 165 148 9 4 4 4 3 1 Dörnyei(2001) 2 3 2 119 2 60 2 4 1 1 30 1 2 2 6 4 3 3.1 5 3 5 90 4 5 120 6 PPT K-POP 3.2 10 40 7 7 2005 10 8 5 9 6 7 3 5 8 9
vol.31_H1-H4.ai
http://www.jmdp.or.jp/ http://www.donorsnet.jp/ CONTENTS 29 8,715 Vol. 31 2 3 ac ad bc bd ab cd 4 Point! Point! Point! 5 Point! Point! 6 7 314 611 122 4 125 2 72 2 102 3 2 260 312 0 3 14 3 14 18 14 60
産衛誌57-4たより.indb
A89 26 7 1 9 4 33 1 87 A90 24 A91 23 ACOH2014 A92 4 1 2 3 4 5 6 7 A93 A94 A95 A96 A97 A98 A99 A100 A101 27 8 1 9 A102 4 33 A103 A104 26 3 140 27 1 A105 27 A106 A107 A108 A109 A110 A111 A112 A113 et al
Fig.1 Procedures of the spot tests for the detection of serum HBV-DNA
Key words: HBV DNA, HBV carrier, HBeAg Fig.1 Procedures of the spot tests for the detection of serum HBV-DNA 昭 和61年2月20日 87 Table 1 Comparison of HBeAg/anti-HBe Fig.2 Comparison of the sensitivity of the
untitled
24 2013116 1 2 23 24 24 (ICRP Publication 101, 57) ICRP Publ.101 Fig.2.1 25 26 ~ (1) (1) 2011311 2011315 葛 楢 () 2012315 2071315 1/2 27 137 Cs () X i = C ia Cs-137 V i i V i 137 Cs A Cs-137 C i A i = C
17 ( ) II III A B C(100 ) 1, 2, 6, 7 II A B (100 ) 2, 5, 6 II A B (80 ) 8 10 I II III A B C(80 ) 1 a 1 = 1 2 a n+1 = a n + 2n + 1 (n = 1,
17 ( ) 17 5 1 4 II III A B C(1 ) 1,, 6, 7 II A B (1 ), 5, 6 II A B (8 ) 8 1 I II III A B C(8 ) 1 a 1 1 a n+1 a n + n + 1 (n 1,,, ) {a n+1 n } (1) a 4 () a n OA OB AOB 6 OAB AB : 1 P OB Q OP AQ R (1) PQ
Taro13-学習ノート表紙.PDF
10 11 12 13 13 14 15 18 22 27 30 32 A B C -1- -2- 1 2 A BC -3- -4- A B C -5- A B C -6- A B C -7- -8- 1-1 1-6 1-2 6-1 1-5 1-3 2-1 6-6 6-2 1-4 2-6 2-2 6-5 6-3 2-5 2-3 6-4 2-4 5-1 3-1 5-6 5-2 3-6 3-2 5-5
140 120 100 80 60 40 20 0 115 107 102 99 95 97 95 97 98 100 64 72 37 60 50 53 50 36 32 18 H18 H19 H20 H21 H22 H23 H24 H25 H26 H27 1 100 () 80 60 40 20 0 1 19 16 10 11 6 8 9 5 10 35 76 83 73 68 46 44 H11
MHC 2013; 20 ( 2 QC QC DNA-QC 3. QCWS 集会参加および参加証明書発行 QCWS QCWS QCWS 解析方法 DNA-QC Luminex SSO SSO SSP SBT QC FlowPRA Lab Screen WAK Flow ICFA 4 HL
Major Histocompatibility Complex 2013; 20 (: 13 16 QCWS # 1. ワークショップの経過 24 1 QCWS HP QCWS 24 2 57 DNA-QC 53 QC 38 1 20 QCWS DNA-QC QC 4 QCWS 4 4 4 16 QCWS 5 21 57 DNA-QC 53 QC 37 5 6 7 HP 8 25 HP 2. QCWS
A B 5 C 9 3.4 7 mm, 89 mm 7/89 = 3.4. π 3 6 π 6 6 = 6 π > 6, π > 3 : π > 3
π 9 3 7 4. π 3................................................. 3.3........................ 3.4 π.................... 4.5..................... 4 7...................... 7..................... 9 3 3. p
10 : 3010 : 54 1F Annex 1! 1 15:3015 : 58 1F Annex 1
4 16 1 10:0010 : 24 1F Annex 1! 2 15:0015 : 24 1F Annex 1!! 10 : 3010 : 54 1F Annex 1! 1 15:3015 : 58 1F Annex 1 ! 2 10:0010 : 28 1F Annex 1 3 15:0015 : 28 1F Annex 1 4 10:3010 : 58 1F Annex 1 1 15:3015
